3D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH

Overview

The aim of the study is to document the left and right ventricular function in patients with sclerodermia associated pulmonal arterial hypertension via 3D echocardiography. The results of this study should help to generate hypothesis for further future studies. The primary hypothesis is that the increased use of modern image guided methods could provide essential aspects for the follow up.

Full Title of Study: “3D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH (EVA 3D Pilot Study)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2019

Detailed Description

The 3D echocardiography could provide early and detailed information about the changes in the left and right ventricle. The prediction of sclerodermia associated pulmonary arterial hypertension (PAH) is rather adverse, so it makes sense to evaluate relevant changes of the left-ventricular longitudinal strain soon to adapt the PAH specific therapy accordingly.

Arms, Groups and Cohorts

  • no treatment

Clinical Trial Outcome Measures

Primary Measures

  • Change of the left ventricular longitudinal strain
    • Time Frame: day 90 (+/- 7 days)
    • echocardiography

Secondary Measures

  • wall thickness
    • Time Frame: 90 days (+/- 7 days)
    • echocardiography
  • left ventricular ejection fracture
    • Time Frame: 90 days (+/- 7 Days)
    • echocardiography
  • left ventricular stroke volume
    • Time Frame: 90 days (+/- 7 days)
    • echocardiography
  • Tricuspid Annular Plane Systolic Excursion (TAPSE)
    • Time Frame: 90 days (+/- 7 days)
    • echocardiography
  • right ventricular fractional area change
    • Time Frame: 90 (+/- 7 days)
    • echocardiography

Participating in This Clinical Trial

Inclusion Criteria

  • age >17 – pulmonary arterial hypertension (PAH) associated with WHO group 1 who start a parenteral prostanoid-therapy – written informed consent – prostanoid naive – no change of the PAH specific therapy within 3 weeks of the recruitment to the study Exclusion Criteria:

  • pregnancy and lactation period – Women of child bearing potential who do not use an effective and secure method for birth control – severe chronic kidney insufficiency (glomerular filtration rate <30), which will remain for more than 3 months – liver-insufficiency Child C – life expectancy shorter than the course of the study (for example because of malignant disease

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Regina Steringer-Mascherbauer
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Regina Steringer-Mascherbauer, OA Dr. – Elisabethinen Hospital
  • Overall Official(s)
    • Regina Steringer-Mascherbauer, MD, Principal Investigator, Krankenhaus der Elisabethinen Linz GmbH
  • Overall Contact(s)
    • Regina Steringer-Mascherbauer, MD, 0043/732/7676, regina.mascherbauer@elisabethinen.or.at

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.